Preprints.org

Oral Wegovy is associated with greater early weight loss than Foundayo in propensity matched adult GLP-1 users

At a glance

At 90 days, mean weight change was -3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), a 3.55-percentage-point difference. These small follow-up subsets limit generalization.

The research question

How do early weight trajectories and documented clinical findings compare after oral Wegovy versus Foundayo initiation in routine care?

Background/Objectives

Oral semaglutide (Wegovy pill) and orforglipron (Foundayo) were recently approved for chronic weight management. Their safety and effectiveness have not been evaluated in real-world practice, particularly during the first few months when dose escalation, early treatment response, and tolerability may shape adherence and subsequent treatment persistence.

Methods

We retrospectively analyzed de-identified electronic health records through September 2026, including 16,220 oral Wegovy and 1,106 Foundayo recipients. Propensity matching on demographics, baseline characteristics including cardiometabolic burden, incretin history, the date of treatment initiation, and clinical visit frequency yielded 756 adult patients per drug. Clinical notes were curated with large language models (LLM), with outputs validated by physician adjudication.

Results

In the unmatched cohorts, prior incretin exposure was recorded in 56.0% of oral Wegovy users versus 63.8% of Foundayo users (P<0.001). Prior injectable Wegovy use predominated among subsequent oral Wegovy users, whereas prior Zepbound use predominated among subsequent Foundayo users (both P<0.001). Dose escalation by day-90 lagged the recommended schedules for both agents. In matched cohorts, despite similar pre-treatment weight trajectories, mean weight change by 90 days after GLP-1 pill initiation was −3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), corresponding to a 3.55-percentage-point difference (95% CI, 1.02-6.08; P=0.007). Post-treatment initiation, LLM-curated clinical notes with physician adjudication confirmed weight-gain in a higher percentage of Foundayo users (5.3%) than oral Wegovy users (2.4%) (RR 2.20; P=0.016). Higher documentation of abnormal lipids was also evident from the LLM-curated notes among Foundayo users (1.7%) versus oral Wegovy users (<1.4%) (RR>5; P=0.009). Serial diagnostic lab testing showed a decrease in triglycerides during oral Wegovy use (−31.6 mg/dL; P=0.011, n=19) and a decrease in non-HDL cholesterol during Foundayo use (−30.5 mg/dL; P=0.04, n=11). Statins use did not meaningfully change upon Foundayo initiation, whereas significant statin-record frequency decrease was observed upon oral Wegovy prescribing (4.8% to 1.8%; P=0.020). Among Foundayo users, those with post-index statin co-prescriptions had numerically higher documented prevalence of abnormal lipids as expected, but also dizziness, and elevated liver enzymes than those without post-index statin co-prescriptions. Furthermore, adverse liver events and elevated liver enzymes were also numerically more frequent among Foundayo users than matched oral Wegovy users, presenting an emerging hypothesis that warrants prospective validation considering the FDA's postmarketing requirement to evaluate Foundayo liver safety and a subsequent FDA adverse-event report of hepatic failure.

Conclusions

In a small subset of patients with follow-up weight measurements approximately 90 days after treatment initiation, oral Wegovy was associated with greater weight loss than Foundayo in routine care. Larger-scale and prospective follow-up analyses are warranted to more robustly compare the safety and effectiveness of these agents.

Limitations & interpretation

Preprint; not peer reviewed. The 90-day comparison included only 3.4% and 2.4% of the matched cohorts. Selective follow-up, residual confounding, uncertain medication intake, and differences in dose escalation limit causal inference. Note-derived findings describe documented prevalence, not adjudicated adverse drug reactions. Exploratory liver and lipid signals do not establish comparative safety effects; larger prospective studies are needed.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
CardiometabolismConference

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

The Menopause Society — 2026 Annual Meeting
October 20, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.